New oral anticoagulants, including apixaban, dabigatran, and rivaroxaban, have been
developed as alternatives to warfarin, the standard oral anticoagulation therapy for patients …

Background—Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are
alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct …

Introduction Non-valvular atrial fibrillation (NVAF) is often accompanied by multiple
comorbid conditions, which increase the associated risks and complexity of patient …

Introduction In the USA, there is a steady rise of atrial fibrillation due to the aging population
with increased morbidity. This study evaluated the risk of stroke/systemic embolism (S/SE) …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Aims The aim of this study was to compare the clinical effectiveness and safety of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice …

Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …

Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …

Objectives With the approval of new non-vitamin K antagonist oral anticoagulants for stroke
prevention in non-valvular atrial fibrillation (NVAF), it is anticipated that their introduction …

Objectives: There is scarce evidence comparing novel oral anticoagulants (NOACs) with
warfarin in real-world settings in Japan. This study compared the risk of bleeding events …